Table: q1_q4_2021_prescription_drug_wac_increases , manufacturer_name like F*

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  *

oshpd_id	manufacturer_name	date_reported	ndc_number	drug_product_description	wac_effective_date	wac_increase_amount	wac_after_increase	patent_expiration_date	drug_source_type	unit_sales_volume_in_us	unit_sales_volume_non_public_indicator	cost_increase_factors	cost_increase_factors_non_public_indicator	change_improvement_description	change_improvement_non_public_indicator	acquisition_date	company_acquired_from	acquisition_price	acquisition_price_non_public_indicator	acquisition_price_comment	wac_at_acquisition	wac_year_prior_to_acquisition	year_drug_introduced_to_market	wac_at_intro_to_market	supporting_documents	general_comments
Rx0000063	Ferring Pharmaceuticals	06/30/2021	55566280001	Cervidil 10MG VAGINAL INSERT (dinoprostone, 10mg)	04/20/2021	21.76	456.99	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"Note: The acquisition fields do not apply because Ferring did not acquire the product within the past five years.
Rx0000063	Ferring Pharmaceuticals	12/31/2021	55566670001	CLENPIQ (sodium picosulfate/magnesium oxide/citric acid) Oral Solution 10 mg-3.5 gram-12 gra,160mL (bottle)	12/30/2021	6.14	159.63	06/26/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000063	Ferring Pharmaceuticals	03/31/2021	55566650003	Endometrin (progesterone) Dosage 100mg suppository (vaginal inserts) 21 inserts 21 applicators	01/08/2021	10.59	275.26	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Ferring initially announced a higher price increase but implemented a lower price increase instead.
Rx0000063	Ferring Pharmaceuticals	06/30/2021	55566750102	MENOPUR (menotropins for injection)/75 units/vial - 5 single-dose vials per package	04/20/2021	41.90	1089.45	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"Note: The acquisition fields do not apply because Ferring did not acquire the product within the past five years. NDC 55566750101 is the NDC for the 0.9% Sodium Chloride Injection, USP, 2 mL product included in the Menopur kit. The Sodium Chloride is used for mixing the medicine. NDC 55566750101 does not have a WAC price. "
Rx0000193	Forte Bio-Pharma, LLC	06/30/2021	72245019310	Nalocet 2.5mg/300mg Tablet 100Ct	05/01/2021	240.35	2643.85	None	Non-innovator Multiple Source Drug	4200	None	Labor Costs- increase workforce of sales representatives	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000193	Forte Bio-Pharma, LLC	06/30/2021	72245019303	Nalocet 2.5mg/300mg Tablet 30Ct	05/01/2021	72.11	793.16	None	Non-innovator Multiple Source Drug	736	None	Labor Costs- increase workforce of sales representatives	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000193	Forte Bio-Pharma, LLC	06/30/2021	72245068310	Prolate 10mg/300mg Tablet 100ct	05/01/2021	240.35	2643.85	None	Non-innovator Multiple Source Drug	6000	None	Labor Costs- increase workforce of sales representatives	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000193	Forte Bio-Pharma, LLC	06/30/2021	72245068110	Prolate 5mg/300mg Tablet 100ct	05/01/2021	240.35	2643.85	None	Non-innovator Multiple Source Drug	1800	None	Labor Costs- increase workforce of sales representatives	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000193	Forte Bio-Pharma, LLC	06/30/2021	72245068210	Prolate 7.5mg/300mg Tablet 100ct	05/01/2021	240.35	2643.85	None	Non-innovator Multiple Source Drug	1500	None	Labor Costs- increase workforce of sales representatives	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000129	Fresenius Kabi USA LLC	12/31/2021	63323036005	1 Vial of 100 ML Intravenous Solution 10%	12/29/2021	4.28	49.28	07/25/2037	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000129	Fresenius Kabi USA LLC	12/31/2021	63323036061	20 Vials of 100 ML Intravenous Solution 10%	12/29/2021	58.60	985.60	07/25/2037	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000129	Fresenius Kabi USA LLC	12/31/2021	63323036059	25 Vials of 50 ML Intravenous Solution 10%	12/29/2021	53.50	616.00	07/25/2037	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000100	Fresenius Medical Care	03/31/2021	49230064331	PHOSLYRA 667MG/5ML ORAL SOLUTION 473ML BOTTLE	01/01/2021	8.12	170.61	02/23/2030	Single Source Drug	None	1	The increase in Wholesale Acquisition Cost (WAC) for the products is due to increases in the costs of manufacturing and distribution, specifically including increases in the cost of the active pharmaceutical ingredients (API) of the products, increases in shipping for the products, and increases in costs to market the products.	None	This WAC increase is not necessitated by a change or improvement in the prescription drug.	None	None	None	None	None	None	None	None	None	None	None	Please note that this report and its contents are exempted from disclosure under the California Public Records Act, Cal. Gov. Code § 6250 et seq. (“PRA”) as the material contains and constitutes FUSA’s proprietary commercial information and otherwise would not be in the public interest to disclose. Please contact Domenic Gaeta at domenic.gaeta@fmc-na.com regarding any PRA requests so that we may take appropriate steps to protect such information. Fresenius Medical Care did not acquire Phoslyra in the prior five year period.
Rx0000100	Fresenius Medical Care	03/31/2021	49230064551	VELPHORO 500MG CHEWABLE TABLETS 90 TABLET BOTTLE	01/01/2021	68.74	1443.51	01/23/2030	Single Source Drug	None	1	The increase in Wholesale Acquisition Cost (WAC) for the products is due to increases in the costs of manufacturing and distribution, specifically including increases in the cost of the active pharmaceutical ingredients (API) of the products, increases in shipping for the products, and increases in costs to market the products.	None	This WAC increase is not necessitated by a change or improvement in the prescription drug.	None	None	None	None	None	None	None	None	None	None	None	Please note that this report and its contents are exempted from disclosure under the California Public Records Act, Cal. Gov. Code § 6250 et seq. (“PRA”) as the material contains and constitutes FUSA’s proprietary commercial information and otherwise would not be in the public interest to disclose. Please contact Domenic Gaeta at domenic.gaeta@fmc-na.com regarding any PRA requests so that we may take appropriate steps to protect such information. Fresenius Medical Care is the authorized distributor for Velphoro. Fresenius Medical Care did not acquire Velphoro in the prior five year period.